239 related articles for article (PubMed ID: 26031918)
1. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.
Cho BS; Zeng Z; Mu H; Wang Z; Konoplev S; McQueen T; Protopopova M; Cortes J; Marszalek JR; Peng SB; Ma W; Davis RE; Thornton DE; Andreeff M; Konopleva M
Blood; 2015 Jul; 126(2):222-32. PubMed ID: 26031918
[TBL] [Abstract][Full Text] [Related]
2. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models.
Peng SB; Zhang X; Paul D; Kays LM; Gough W; Stewart J; Uhlik MT; Chen Q; Hui YH; Zamek-Gliszczynski MJ; Wijsman JA; Credille KM; Yan LZ
Mol Cancer Ther; 2015 Feb; 14(2):480-90. PubMed ID: 25504752
[TBL] [Abstract][Full Text] [Related]
3. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
Zeng Z; Shi YX; Samudio IJ; Wang RY; Ling X; Frolova O; Levis M; Rubin JB; Negrin RR; Estey EH; Konoplev S; Andreeff M; Konopleva M
Blood; 2009 Jun; 113(24):6215-24. PubMed ID: 18955566
[TBL] [Abstract][Full Text] [Related]
4. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia.
Chen Y; Jacamo R; Konopleva M; Garzon R; Croce C; Andreeff M
J Clin Invest; 2013 Jun; 123(6):2395-407. PubMed ID: 23676502
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.
Zeng Z; Samudio IJ; Munsell M; An J; Huang Z; Estey E; Andreeff M; Konopleva M
Mol Cancer Ther; 2006 Dec; 5(12):3113-21. PubMed ID: 17172414
[TBL] [Abstract][Full Text] [Related]
6. CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-b Signaling.
Kim BR; Jung SH; Han AR; Park G; Kim HJ; Yuan B; Battula VL; Andreeff M; Konopleva M; Chung YJ; Cho BS
Cancers (Basel); 2020 Jun; 12(7):. PubMed ID: 32629802
[TBL] [Abstract][Full Text] [Related]
7. Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis.
Li X; Guo H; Duan H; Yang Y; Meng J; Liu J; Wang C; Xu H
Sci Rep; 2015 Nov; 5():16228. PubMed ID: 26538086
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.
Tavor S; Petit I; Porozov S; Avigdor A; Dar A; Leider-Trejo L; Shemtov N; Deutsch V; Naparstek E; Nagler A; Lapidot T
Cancer Res; 2004 Apr; 64(8):2817-24. PubMed ID: 15087398
[TBL] [Abstract][Full Text] [Related]
9. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
[TBL] [Abstract][Full Text] [Related]
10. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation.
Tavor S; Eisenbach M; Jacob-Hirsch J; Golan T; Petit I; Benzion K; Kay S; Baron S; Amariglio N; Deutsch V; Naparstek E; Rechavi G
Leukemia; 2008 Dec; 22(12):2151-5158. PubMed ID: 18769446
[TBL] [Abstract][Full Text] [Related]
11. Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists.
Mandawat A; Fiskus W; Buckley KM; Robbins K; Rao R; Balusu R; Navenot JM; Wang ZX; Ustun C; Chong DG; Atadja P; Fujii N; Peiper SC; Bhalla K
Blood; 2010 Dec; 116(24):5306-15. PubMed ID: 20810927
[TBL] [Abstract][Full Text] [Related]
12. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
Ladikou EE; Chevassut T; Pepper CJ; Pepper AG
Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579
[TBL] [Abstract][Full Text] [Related]
13. POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL.
Sison EA; Magoon D; Li L; Annesley CE; Romagnoli B; Douglas GJ; Tuffin G; Zimmermann J; Brown P
Oncotarget; 2015 Oct; 6(31):30902-18. PubMed ID: 26360610
[TBL] [Abstract][Full Text] [Related]
14. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.
Sison EA; McIntyre E; Magoon D; Brown P
Mol Cancer Res; 2013 Sep; 11(9):1004-16. PubMed ID: 23754844
[TBL] [Abstract][Full Text] [Related]
15. A novel dimeric CXCR4 antagonist synergizes with chemotherapy in acute myeloid leukaemia by mobilizing leukaemic cells from their associated bone marrow niches.
Huang Y; Huang Z; An J; Xu Y
Br J Haematol; 2019 Oct; 187(1):e11-e15. PubMed ID: 31388999
[No Abstract] [Full Text] [Related]
16. Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells.
Liesveld JL; Bechelli J; Rosell K; Lu C; Bridger G; Phillips G; Abboud CN
Leuk Res; 2007 Nov; 31(11):1553-63. PubMed ID: 17403536
[TBL] [Abstract][Full Text] [Related]
17. Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia.
Landry B; Gül-Uludağ H; Plianwong S; Kucharski C; Zak Z; Parmar MB; Kutsch O; Jiang H; Brandwein J; Uludağ H
J Control Release; 2016 Feb; 224():8-21. PubMed ID: 26742943
[TBL] [Abstract][Full Text] [Related]
18. Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587.
Peng SB; Van Horn RD; Yin T; Brown RM; Roell WC; Obungu VH; Ruegg C; Wroblewski VJ; Raddad E; Stille JR
Oncotarget; 2017 Nov; 8(55):94619-94634. PubMed ID: 29212254
[TBL] [Abstract][Full Text] [Related]
19. Functional CXCR4-expressing microparticles and SDF-1 correlate with circulating acute myelogenous leukemia cells.
Kalinkovich A; Tavor S; Avigdor A; Kahn J; Brill A; Petit I; Goichberg P; Tesio M; Netzer N; Naparstek E; Hardan I; Nagler A; Resnick I; Tsimanis A; Lapidot T
Cancer Res; 2006 Nov; 66(22):11013-20. PubMed ID: 17108140
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte colony-stimulating factor inhibits CXCR4/SDF-1α signaling and overcomes stromal-mediated drug resistance in the HL-60 cell line.
Sheng X; Zhong H; Wan H; Zhong J; Chen F
Exp Ther Med; 2016 Jul; 12(1):396-404. PubMed ID: 27347068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]